Molecular Imaging of Renal Malignancy: A Review
- 26 Downloads
Purpose of Review
Renal cell carcinoma (RCC) is a common malignancy that is often detected incidentally in patients undergoing cross-sectional imaging of the abdomen for workup of pain or other symptoms. Due to overlap in imaging findings of RCC and benign tumors, biopsy may be necessary to confirm the diagnosis. Biopsies are occasionally non-diagnostic, however, and in small lesions or patients with comorbidities may not be technically feasible. Molecular imaging techniques can characterize tumors as being more likely malignant or benign and obviate the need for invasive testing, as well as providing accurate whole-body staging in patients with known RCC.
PET/CT with 18F-FDG and other radionuclides can identify primary renal masses with higher malignant potential and also allows for sensitive detection of metastatic RCC. SPECT/CT imaging with 99mTc-sestamibi can provide useful information to support the diagnosis of benign oncocytic neoplasms over more aggressive RCC subtypes. Investigational molecular imaging techniques such as immunoPET and hyperpolarized 13C MRI have also shown promise in renal mass characterization.
This review article aims to outline the various molecular imaging modalities available in the evaluation of primary renal tumors and in whole-body staging of metastatic RCC.
KeywordsRCC Renal cell carcinoma FDG PET PET/CT Molecular imaging
The authors acknowledge Dr. Steven Rowe for contributing the cases as shown in Fig. 4.
Compliance with Ethics Guidelines
Conflict of interest
Spencer C. Behr reports grants from Cancer Targeted Technology and GE Healthcare and is a consultant for QED Therapeutics. Robert R. Flavell is a section editor for Current Radiology Reports. C. Elias Graybiel and Zhen J. Wang each declare no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Recently published papers of particular interest have been highlighted as: • Of importance
- 3.• Shinagare AB, Krajewski KM, Braschi-Amirfarzan M, Ramaiya NH. Advanced renal cell carcinoma: role of the radiologist in the era of precision medicine. Radiology. 2017;284(2):333–51. https://doi.org/10.1148/radiol.2017160343. Provides an overview of the pathophysiology of the various RCC subtypes, imaging features, and current therapies employed for treating advanced RCC.
- 5.Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8(4):304–10. https://doi.org/10.1016/s1470-2045(07)70044-x.CrossRefPubMedGoogle Scholar
- 7.Win AZ, Aparici CM. Clinical effectiveness of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in management of renal cell carcinoma: a single institution experience. World J Nucl Med. 2015;14(1):36–40. https://doi.org/10.4103/1450-1147.150535.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Tirumani SH, Souza D, Krajewski KM, Jagannathan JP, Ramaiya NH, Shinagare AB. Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients. Abdom Radiol. 2016;41(2):295–302. https://doi.org/10.1007/s00261-015-0569-7.CrossRefGoogle Scholar
- 10.• Campbell S, Uzzo RG, Allaf ME, Bass EB, Cadeddu JA, Chang A, et al. Renal mass and localized renal cancer: AUA guideline. J Urol. 2017;198(3):520–9. https://doi.org/10.1016/j.juro.2017.04.100. Provides an update on the American Urological Association guidelines for management of renal masses and localized RCC.
- 12.Sun MRM, Ngo L, Genega EM, Atkins MB, Finn ME, Rofsky NM, et al. Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes; correlation with pathologic findings. Radiology. 2009;250(3):793–802. https://doi.org/10.1148/radiol.2503080995.CrossRefPubMedGoogle Scholar
- 14.• Liu Y. The place of FDG PET/CT in renal cell carcinoma: value and limitations. Front Oncol. 2016;6(201):1–7. https://doi.org/10.3389/fonc.2016.00201. Provides a review of the utility of FDG PET in evaluating primary RCC, in addition to RCC staging and restaging.
- 18.Aide N, Cappele O, Bottet P, Bensadoun H, Regeasse A, Comoz F, et al. Efficiency of [18F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging. 2003;30(9):1236–45. https://doi.org/10.1007/s00259-003-1211-4.CrossRefPubMedGoogle Scholar
- 21.Pan J, Lau J, Mesak F, Hundal N, Pourghiasian M, Liu Z, et al. Synthesis and evaluation of 18F-labeled carbonic anhydrase IX inhibitors for imaging with positron emission tomography. J Enzyme Inhib Med Chem. 2014;29(2):249–55. https://doi.org/10.3109/14756366.2013.773994.CrossRefPubMedGoogle Scholar
- 24.Spatz S, Tolkach Y, Jung K, Stephan C, Busch J, Ralla B, et al. Comprehensive evaluation of prostate specific membrane antigen expression in the vasculature of renal tumors: implications for imaging studies and prognostic role. J Urol. 2018;199(2):370–7. https://doi.org/10.1016/j.juro.2017.08.079.CrossRefPubMedGoogle Scholar
- 26.Sawicki LM, Buchbender C, Boos J, Giessing M, Ermert J, Antke C, et al. Diagnostic potential of PET/CT using a 68-Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience. Eur J Nucl Med Mol Imaging. 2017;44(1):102–7. https://doi.org/10.1007/s00259-016-3360-2.CrossRefPubMedGoogle Scholar
- 27.Behr SC, Aggarwal R, VanBrocklin HF, Flavell RR, Gao K, Small EJ, et al. First-in-human phase I study of CTT1057, a novel 18F labeled imaging agent with phosphoramidate core targeting prostate specific membrane antigen in prostate cancer. J Nucl Med. 2018. https://doi.org/10.2967/jnumed.118.220715. [Epub ahead of print].
- 29.Sheikhbahaei S, Jones CS, Porter KK, Rowe SP, Gorin MA, Baras AS, et al. Defining the added value of 99mTc-MIBI SPECT/CT to conventional cross-sectional imaging in the characterization of enhancing solid renal masses. Clin Nucl Med. 2017;42(4):e188–93. https://doi.org/10.1097/rlu.0000000000001534.CrossRefPubMedGoogle Scholar
- 31.• Gorin MA, Rowe SP, Baras AS, Solnes LB, Ball MW, Pierorazio PM, et al. Prospective evaluation of 99mTc-sestamibi SPECT/CT for the diagnosis of renal oncocytomas and hybrid oncocytic/chromophobe tumors. Eur Urol. 2016;69(3):413–6. https://doi.org/10.1016/j.eururo.2015.08.056. provides the basis for 99m Tc-sestamibi SPECT/CT in differentiating benign renal tumors and indolent RCC from ccRCC.
- 32.Tzortzakakis A, Gustafsson O, Karlsson M, Ekstrom-Ehn L, Ghaffarpour R, Axelsson R. Visual evaluation and differentiation of renal oncocytomas from renal cell carcinomas by means of 99mTc-sestamibi SPECT/CT. EJNMMI Res. 2017;7(29):1–5. https://doi.org/10.1186/s13550-017-0278-z.CrossRefGoogle Scholar
- 33.Sriram R, Gordon J, Baligand C, Ahamed F, Delos Santos J, Qin H, et al. Non-invasive assessment of lactate production and compartmentalization in renal cell carcinomas using hyperpolarized 13C pyruvate MRI. Cancers (Basel). 2018;10(9):313. https://doi.org/10.3390/cancers10090313.CrossRefPubMedCentralGoogle Scholar
- 36.Wettersten HI, Hakimi AA, Morin D, Bianchi C, Johnstone ME, Donohoe DR, et al. Grade-dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis. Cancer Res. 2015;75(12):2541–52. https://doi.org/10.1158/0008-5472.can-14-1703.CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Gerlinger M, Santos CR, Spencer-Dene B, Martinez P, Endesfelder D, Burrell RA, et al. Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J Pathol. 2012;227(2):146–56. https://doi.org/10.1002/path.4006.CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Keshari KR, Sriram R, Koelsch BL, Van Criekinge M, Wilson DM, Kurhanewicz J, et al. Hyperpolarized 13C-pyruvate magnetic resonance reveals rapid lactate export in metastatic renal cell carcinomas. Cancer Res. 2013;73(2):529–38. https://doi.org/10.1158/0008-5472.can-12-3461.CrossRefPubMedGoogle Scholar